DULUTH, Ga., Jan. 26 /PRNewswire/ -- Banking on a solid business model, team expertise and the promise of delivering extended value over the long term to its partners, StoneBridge Pharma, LLC has emerged as a new player in the specialty pharmaceutical sector.
StoneBridge Pharma's goal is to partner with other pharmaceutical companies, drug development and delivery companies, active pharmaceutical ingredients manufacturers, and contract manufacturers to help them get extended returns from their intellectual property. The company will help partners throughout a product's lifecycle, from the time of initial development to launching new delivery methods and formulations for proven compounds, to providing re-launch of late lifecycle products.
"We know that our model will work," said Rick Coulon, StoneBridge Pharma's director of marketing. "There are many companies with proven, reliable brands that are nearing the end of their natural product lifecycle. Typically, these companies choose to dedicate their resources to new products and to no longer promote their mature brands. Others develop products but never had the resources to maximize their sales. And then there are those companies with the right ideas and molecules, but no ability to effectively bring them to market."
Coulon explained that these companies should see StoneBridge Pharma as "an excellent alternative to internal resources, which may look past opportunities due to limited market potential."
StoneBridge Pharma's initial ventures will be in ophthalmology and gastroenterology with a focus on launching products with $5-50 million sales potential. Initial product launch dates are scheduled for Q2 2006.
StoneBridge Pharma has a simple - yet powerful - business strategy:
1. Seek partnerships with companies that have successful, and proven
products ranging from those that are losing momentum or patent
exclusivity in the near future to others that never had their full
2. Use the knowledge and expertise of a management team with more than a
century of collective experience in the pharmaceutical industry.
3. Maximize the performance of a specialized and highly targeted sales and
4. Use existing infrastructure such as contract administration, trade
operations, sales force automation, sales training, sample
accountability, and other existing management in order to maximize
efficiency and return on investment.
5. Use a variety of approaches to revitalize and re-market products, such
* Marketing new drug delivery methods or formulations (for example,
changing a product to be free of preservatives, or altering it for
once-a-day dosing instead of three times a day)
* Initiate special sales and marketing programs through the focused
* Take drugs to their final stage after being marketed as a name brand
(i.e. lifecycle optimization from brands through generic stages).
"StoneBridge Pharma will create partnerships to revitalize these necessary, useful treatments and keep them in the minds of doctors and patients," said Robert Sykora, RPh, StoneBridge Pharma's vice president of sales and marketing. "Of paramount importance, however, is that our business partners know we are grounded in trustworthiness and integrity."
Companies interested in working with StoneBridge Pharma can contact the company at 866-436-0318. The company's web site is http://www.stonebridgepharma.com.
StoneBridge Pharma, LLC